RxDoctor Payments Data

Penelope Kagan

Internal Medicine · Brockton, MANPI 1194341008

Payments from drug & device makers

$6,828in general payments, 2019–2025

Across 360 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$867
  • Novo Nordisk$663
  • Pfizer$648
  • AstraZeneca$639
  • Lilly USA, LLC$553
  • Novartis$463
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,828 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$147,958
Medicare patients
371
Services billed
3,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$121,877
EliquisApixaban20$29,358
JardianceEmpagliflozin18$20,475
MyrbetriqMirabegron12$11,504
MounjaroTirzepatide11$11,416
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,341
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,080
Atorvastatin Calcium120$1,458
Rosuvastatin Calcium58$1,365
Oxycodone Hcl53$1,231
Gabapentin76$1,230
Albuterol Sulfate HfaAlbuterol Sulfate39$1,078
Fentanyl14$960
Duloxetine Hcl37$908
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$663$121,877117 claims
PfizerEliquis$648$29,35820 claims
Boehringer IngelheimJardiance$42$20,47518 claims
Lilly USA, LLCMounjaro$553$11,41611 claims
GSKTrelegy Ellipta$204$8,34113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brockton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →